“…For instance, in Nigeria, where Type I FGM/C is common, medicalisation is not being driven by parents' concerns about safety of the practice (it is already seen as a relatively benign practice) (Obianwu, personal communication). Instead, as women seek medicalised delivery services, FGM/C is being offered as part of routine neonatal services (Obianwu, Adetunji, Dirisu, Ishaku, & Adebajo, 2017). By contrast, in Egypt and Sudan, medicalisation has been linked to policies aimed at regulating harm (Bedri and Mohamed, personal communication, Hussein, personal communication), and may entrench the practise of FGM/C (Bedri, Sherfi, Elhadi, Rodwan, & Elamin, In preparation; El-Gibaly & Aziz, In preparation).…”